Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours.

Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours.

no === PURPOSE: C-1311 is a member of the novel imidazoacridinone family of anticancer agents. This phase 1 trial was designed to investigate the safety, tolerability and preliminary anti-tumour activity of C-1311. PATIENTS AND METHODS: This was a phase 1, inter-subject dose escalating and pharma...

Full description

Bibliographic Details
Main Authors: Isambert, N., Campone, M., Bourbouloux, E., Drouin, M., Major, A., Yin, W., Loadman, Paul M., Capizzi, R., Grieshaber, C., Fumoleau, P.
Language:en
Published: Elsevier 2010
Subjects:
C1311
Phase 1 study
Anticancer agents
Anti-tumour activity
Pharmacokinetics
Imidazoacridinone
Safety and tolerability
Online Access:http://hdl.handle.net/10454/4563

Internet

http://hdl.handle.net/10454/4563

Similar Items